Five-Year Lecanemab Data Presented at CTAD 2026
New long-term extension data on lecanemab in early Alzheimer's disease were presented at CTAD 2026. The supplied text says treatment benefits accrue over time.
New long-term extension data on lecanemab in early Alzheimer's disease were presented at CTAD 2026. The supplied text says treatment benefits accrue over time.